48.72

0.61% -0.30

After Hours: 48.81 0.09 +0.18%

Spruce Biosciences Inc (SPRB)

Overview News Price History Financials Discussions Forecast

Spruce Biosciences Inc stock is traded at $48.72, with a volume of 37,188. It is down -0.61% in the last 24 hours and down -23.15% over the past month. Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company develops biologics and small-molecule product candidates aimed at addressing diseases with unmet medical needs and limited or no approved therapies. Its product candidate, TA-ERT for the treatment of Mucopolysaccharidosis Type IIIB (MPS IIIB), is a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase (rhNAGLU) intended as an enzyme replacement therapy for patients who lack rhNAGLU enzyme activity. TA-ERT is designed to restore rhNAGLU enzyme activity in the central nervous system following intracerebroventricular injection and promote clearance of heparan sulfate in the brain.

Previous Close:

$49.02

Open:

$49.22

24h Volume:

37,188

Relative Volume:

0.46

Market Cap:

$140.02M

Revenue:

$697.00K

Net Income/Loss:

$-37.19M

P/E Ratio:

-1.2925

EPS:

-37.6952

Net Cash Flow:

$-29.34M

1W Performance:

-8.16%

1M Performance:

-23.15%

6M Performance:

-30.37%

1Y Performance:

+528.65%

1-Day Range:

$47.54

$49.31

1-Week Range:

$45.01

$55.05

52-Week Range:

$7.26

$240.00

Spruce Biosciences Inc Stock (SPRB) Company Profile

Name

Spruce Biosciences Inc

Sector

Healthcare (1067)

Industry

Biotechnology (595)

Phone

(415) 655-4168

Address

611 GATEWAY BOULEVARD, SUITE 740, SOUTH SAN FRANCISCO

Employee

Twitter

Next Earnings Date

2026-11-09

Latest SEC Filings

SPRB's Discussions on Twitter

Compare SPRB vs VRTX, REGN, MRNA, ARGX, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SPRB Spruce Biosciences Inc	48.72	140.02M	697.00K	-37.19M	-29.34M	-37.70
VRTX Vertex Pharmaceuticals Inc	526.19	133.37B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	788.04	81.13B	14.92B	4.42B	3.79B	41.04
MRNA Moderna Inc	198.88	79.40B	2.23B	-3.19B	-1.60B	-8.1462
ARGX Argen X Se Adr	959.49	60.03B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	204.97	43.93B	742.00K	-1.37B	-1.07B	-7.0731

Spruce Biosciences Inc Stock (SPRB) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-27-26	Initiated	Craig Hallum	Buy
Dec-23-25	Initiated	Oppenheimer	Outperform
Dec-03-25	Upgrade	Leerink Partners	Market Perform → Outperform
Oct-28-25	Upgrade	Citizens JMP	Mkt Perform → Mkt Outperform
Dec-11-24	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Dec-11-24	Downgrade	Oppenheimer	Outperform → Perform
Mar-14-24	Downgrade	Guggenheim	Buy → Neutral
Mar-14-24	Downgrade	H.C. Wainwright	Buy → Neutral
Mar-14-24	Downgrade	Ladenburg Thalmann	Buy → Neutral
Mar-14-24	Downgrade	Leerink Partners	Outperform → Market Perform
Mar-14-24	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Feb-21-24	Initiated	Guggenheim	Buy
Dec-17-21	Initiated	Oppenheimer	Outperform
Dec-10-21	Initiated	The Benchmark Company	Speculative Buy
Nov-16-21	Downgrade	SVB Leerink	Outperform → Mkt Perform
Jul-19-21	Initiated	H.C. Wainwright	Buy
Apr-26-21	Resumed	Credit Suisse	Outperform
Nov-03-20	Initiated	Cowen	Outperform
Nov-03-20	Initiated	Credit Suisse	Outperform
Nov-03-20	Initiated	RBC Capital Mkts	Outperform
Nov-03-20	Initiated	SVB Leerink	Outperform

View All

Spruce Biosciences Inc Stock (SPRB) Latest News

Sep 24, 2026

SPRB Reiterated by Citizens -- Price Target Maintained at $144 - GuruFocus

Sep 24, 2026

Citizens reiterates Spruce Biosciences stock rating on therapy lead - Investing.com

Sep 24, 2026

Sep 20, 2026

Spruce Biosciences, Inc.(NasdaqCM: SPRB) added to S&P Global BMI Index - marketscreener.com

Sep 20, 2026

Sep 18, 2026

Spruce Biosciences Stock Price Forecast. Should You Buy SPRB? - StockInvest.us

Sep 18, 2026

Lake Street Initiates Spruce Biosciences at Buy With $149 Price Target - Yahoo Finance

Sep 18, 2026

Citizens reiterates Spruce Biosciences stock rating on gene therapy approval - Investing.com

Sep 18, 2026

Citizens reiterates Spruce Biosciences stock rating on gene therapy approval By Investing.com - Investing.com Canada

Sep 18, 2026

Sep 17, 2026

SPRB Initiated Coverage by Lake Street -- Price Target Announced at $149 - GuruFocus

Sep 17, 2026

Spruce Biosciences Initiated at Buy by Lake Street - Moomoo

Sep 17, 2026

Lake Street Initiates Spruce Biosciences(SPRB.US) With Buy Rating, Announces Target Price $149 - Moomoo

Sep 17, 2026

Spruce Biosciences at H.C. Wainwright: BLA path comes into focus By Investing.com - Investing.com Canada

Sep 17, 2026